| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | 0.098 | 0.002 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.21 | 0.004 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | 0.13 | 0.005 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.11 | 0.005 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.15 | 0.005 |